Dream C&S has revised its clinical trial outsourcing contract, reducing the contract amount by approximately 286 million won

Dream C&S (stock code 223250) submitted a revised disclosure on August 11, 2026, regarding the adjustment of the contract amount for a clinical trial outsourcing agreement signed with a U.S. pharmaceutical company. The original disclosure was submitted on May 9, 2025, and the reason for this revision is a change in the contract amount due to an adjustment in the scope of the outsourced work. Prior to the revision, the finalized contract amount was 7,228,784,120 won (27.64% of revenue), but after the revision, it is 6,942,892,720 won (26.55% of revenue), a decrease of approximately 285,891,400 won. The most recent revenue used as a benchmark is approximately 261.53 billion won, based on the consolidated financial statements for the business year ending in December 2021. This contract, signed on July 14, 2022, is a clinical trial outsourcing agreement, and the scheduled termination date is September 10, 2029. However, the company stated that the contract period is aligned with the target (expected) schedule, and the actual contract period will extend until all entrusted tasks are completed. Payment is made in cash based on the progress of the work, and there are no upfront payments or deposits. The counterparty is a U.S.-based pharmaceutical company, and detailed information such as the company name, recent revenue, and relationship with the company has not been disclosed due to confidentiality requests. However, it has been confirmed that the company has a track record of similar contracts with this counterparty over the past three years. The period for which the contract is subject to reservation is also until September 10, 2029, and information about the counterparty will remain confidential until the contract is terminated. Dream C&S is performing this contract using its own production methods, and this revision only reflects the change in amount due to the adjustment in the scope of work, without any changes to the contract structure or duration. Related disclosures have been updated since the initial disclosure in July 2022, and were also renewed in May 2024 and May 2025.